Positron emission tomography for assessment of viability

Current Opinion in Cardiology

Volumn 21, Issue 5, 2006, Pages 464-468

  Sawada, Stephen G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Myocardial viability; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE DERIVATIVE; TRACER;

CARDIOVASCULAR RISK; CHRONIC DISEASE; CONVALESCENCE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG UPTAKE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MYOCARDIAL HIBERNATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; SYSTOLE; TISSUE CHARACTERIZATION;

CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TISSUE SURVIVAL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33747052580     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000240583.91591.a8     Document Type: Review

References (36)

1. Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91:1697-1705.
2. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990; 31:1749-1756.
3. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 33:1255-1262.
4. Marwick TH, MacIntyre WJ, Lafont A, et al.Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function and metabolism. Circulation 1998; 5:1347-1355.
5. Canty JM, Fallovollita JA. Lessons from experimental models of hibernating myocardium. Coron Artery Dis 2001; 12:371-380.
6. Schwaiger M, Brunken R, Grover-McKay M, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986; 8:800-808.
7. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron emission tomography. N Engl J Med 1986; 314:884-888.
8. Camici PG, Rimoldi O. Myocardial hibernation vs repetitive stunning in patients. Card in Review 1999; 7:39-43.
9. Vanoverschelde J-LJ. Wijns W, Depre C, et al. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993; 87:1513-1523.
10. Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 2001; 104 (suppl. 1):I314-318.
11. Schwarz ER, Schoendube FA, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol 1998; 31:1018-1026.
12. Perrrone-filardi P, Bacharach SL, Dilsizian V, et al. Clinical significance of reduced myocardial glucose uptake in regions with normal blood flow in patients with chronic coronary artery disease. J Am Coll Cardiol 1994; 23:608-616.
13. Knuuti MJ, Saraste M, Nuutila P, et al. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994; 127:785-796.
14. 18F SPECT and PET: implications for myocardial viability assessment. J Nucl Med 2001; 42:1579-1585.
15. Bax JJ, Wijns W, Cornel JH, et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30:1451-1460.
16. Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26:141-186.
17. Knuuti J, Schelbert H, Bax JJ. The need for standardization of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Med 2002; 29:1257-1266.
18. Bax JJ, Poldermans D, Visser FC, et al. Relation between preoperative viability and postoperative improvement of LVEF and heart failure symptoms. J Nucl Med 2001; 42:79-86.
19. Beanlands RSB, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40:1735-1743.
20. Klein C, Nekolla SG, Bengel FM, et al. Assesment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002; 105:162-167.
21. Knuesel PR, Nanz D, Wyss C, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 2003; 108:1095-1100.
22. Eitzman D, Ziad Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20:559-565.
23. Dicarli M, Davidson M, Little R, et al. Value ofmetabolic imagingwith positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73:527-533.
24. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158.
25. DiCarli MF, Asgarzadie F, Schelbert H, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92:3436-3444.
26. Marwick TH, Nemec JJ, Lafont A, et al. Prediction of improvement in exercise capacity after revascularization. Am J Cardiol 1992; 69:854-859.
27. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30:1693-1700.
28. Beanlands RSB, Hendry PJ, Masters RG, et al. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 1998; 19 (suppl.): II51-II56.
29. Sawada S, Hamoui O, Barclay J, et al. Usefulness of positron emission tomography in predicting long-term outcome in patients with diabetes mellitus and ischemic left ventricular dysfunction. Am J Cardiol 2005; 96:2-8. FDG imaging was successful in 97% of diabetics using bolus insulin doses.
30. Schoder H, Campisi R, Ohtake T, et al. Blood-flow metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol 1999; 33:1328-1337.
31. •].
32. Machac J. Cardiac positron emission tomography imaging. Sem Nucl Med 2005; 35:17-35.
33. Mabuchi M, Kubo N, Morita K, et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Comm 2002; 23:879-885.
34. Hickey KT, Sciacca RR, Bokhari S, et al. Assessment of cardiac wall motion and ejection fraction with gated PET using N-13 ammonia. Clin Nucl Med 2004; 29:243-248.
35. Schaefer WM, Lipke CSA, Nowak B, et al. Validation of an evaluation routine for left ventricular volumes, ejection fraction and wall motion from gated cardiac FDG PET: a comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2003; 30:545-553.
36. Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using 18F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Eur Heart J 2001; 22:1691-1701.